DE GRUYTER Clinical Chemistry and Laboratory Medicine

Operation Moonshot: Rapid translation of a SARS-CoV-2 targeted peptide immunoaffinity liquid chromatography-tandem mass spectrometry test from research into routine clinical use.

Journal:	*Clinical Chemistry and Laboratory Medicine*
Manuscript ID	CCLM.2022.1000.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Hällqvist, Jenny; University College London, Translational Mass Spectrometry Research Group Uni; UCL Queen Square Institute of Neurology Lane, Dan; Leicester Royal Infirmary, Department of Chemical Pathology and Metabolic Diseases; University of Leicester, Leicester Diabetes Centre Shapanis, Andrew; University of Southampton, Centre for Proteomic research; University of Southampton, Biological Sciences Davis, Kayleigh; Guy's and St Thomas' NHS Foundation Trust, Biochemical Sciences, Viapath Heywood, Wendy; University College London, Translational Mass Spectrometry Research Group Unit Doykov, Ivan; University College London, Translational Mass Spectrometry Research Group Unit Śpiewak, Justyna; University College London, Translational Mass Spectrometry Research Group Unit Ghansah, Nana; National Hospital for Neurology and Neurosurgery, Neurometabolic Unit Keevil, Brian; Manchester University NHS Foundation Trust, Department of Biochemistry Gupta, Pankaj; Leicester Royal Infirmary, Department of Chemical Pathology and Metabolic Diseases; University of Leicester, Cardiovascular Sciences Jukes-Jones, Rebekah; Leicester Royal Infirmary, Department of Chemical Pathology and Metabolic Diseases; University of Leicester, van Geest MS-OMICS facility Singh, Raj; University of Leicester, van Geest MS-OMICS facility Foley, Dominic; Waters Corp Wilmslow, Health Sciences Vissers, Johannes; Waters Corp Wilmslow Pattison, Rebecca; Waters Corp Wilmslow Ferries, Samantha; Waters Corp Wilmslow Wardle, Robert; Waters Corp Wilmslow Bartlett, Amy; Waters Corp Wilmslow Calton, Lisa; Waters Corp Wilmslow Anderson, Leigh; SISCAPA Assay Technologies Inc Razavi, Morteza; SISCAPA Assay Technologies Inc Pearson, Terry; SISCAPA Assay Technologies Inc

Pope, Matt; SISCAPA Assay Technologies Inc
Yip, Richard; SISCAPA Assay Technologies Inc
Ng, Leong; University of Leicester, Cardiovascular Sciences; University of Leicester, van Geest MS-OMICS Facility
Nicholas, Benjamin; University of Southampton, Centre for Proteomic research
Bailey, Alistair; University of Southampton, Centre for Proteomic research
Noel, Dan; University of Southampton, Biological Sciences
Dalton, Neil; Evelina London Children's Hospital, Well Child Laboratory
Heales, Simon; National Hospital for Neurology and Neurosurgery, Neurometabolic Unit
Hopley, Christopher; LGC Teddington, National Measurement Laboratory
Pitt, Andrew; The University of Manchester Manchester Institute of Biotechnology
Barran, Perdita; The University of Manchester Manchester Institute of Biotechnology
Jones, Donald; University of Leicester, van Geest MS-OMICS Facility
Mills, Kevin; University College London, Translational Mass Spectrometry Research Group Unit
Skipp, Paul; University of Southampton, Centre for Proteomic research; University of Southampton, Biological Sciences
Carling, Rachel; Guy's and Saint Thomas' NHS Foundation Trust, Viapath; Guy's King's and Saint Thomas' School of Medicine, School Medical Education

Section/Category: Method Evaluation

Classifications: 30.116 Liquid chromatography-tandem mass spectrometry < 30.100 Methods < 30 Methods, 30.117 Mass spectrometry < 30.100 Methods < 30 Methods, 30.118 Method comparison < 30.100 Methods < 30 Methods, 30.121 Proteomics < 30.100 Methods < 30 Methods

Keywords: Proteins, Laboratory methods & tools, High performance liquid chromatography, Mass spectrometry

Abstract:

Objectives: During 2020, the UK’s Department of Health and Social Care (DHSC) established the Moonshot programme to fund various diagnostic approaches for the detection of SARS-CoV-2, the pathogen behind the COVID-19 pandemic. Mass spectrometry was one of the technologies proposed to increase testing capacity.
Methods: Moonshot funded a multi-phase development programme, bringing together experts from academia, industry and NHS to develop a state-of-the-art targeted protein assay utilising enrichment and liquid chromatography tandem mass spectrometry (LC-MS/MS) to capture and detect low levels of tryptic peptides derived from SARS-CoV-2 virus. The assay relies on detection of target peptides, ADETQALPQRK (ADE) and AYNVTQAFGR (AYN), derived from the nucleocapsid protein of SARS-CoV-2, measurement of which allowed the specific, sensitive, and robust detection of the virus from nasopharyngeal (NP) swabs. The diagnostic sensitivity and specificity of LC-MS/MS was compared with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) via a prospective study.
Results: Analysis of NP swabs (n=361) with a median RT-qPCR quantification cycle (Cq) of 27 (range 16.7-39.1) demonstrated diagnostic sensitivity of 92.4% (87.4–95.5), specificity of 97.4% (94.0–98.9) and near total concordance with RT-qPCR (Cohen’s Kappa 0.90). Excluding Cq > 32 samples, sensitivity was 97.9% (94.1-99.3), specificity 97.4% (94.0-98.9) and Cohen’s Kappa 0.95.
Conclusions: This unique collaboration between academia, industry and NHS enabled development, translation, and validation of a SARS-CoV-2 method in NP swabs to be achieved in five months. This pilot provides a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	model and pipeline for future accelerated development and implementation of LC-MS/MS protein/peptide assays into the routine clinical laboratory.

SCHOLARONE™
Manuscripts

Strictly adhere to the given format!
In case informed consent or ethical approval do not apply the statements should read: "Not applicable".

Acknowledgments

We would like to thank the Peto Foundation for their kind donations and the NIHR-BRCs at Great Ormond Street Hospital, Leicester, Manchester and Southampton.

Research funding

This work was funded by the UK Department of Health and Social Care (DHSC) as part of the Moonshot programme.

Author contributions

All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests

LC, DF, TM, JV, RP, AB, SF and RW are employed by Waters Corporation. LA, MR, JP and MP are employed by SISCAPA Assay Technologies. SH and RND were advisors to the DHSC for the duration of this project. None of the other authors declared any potential conflicts of interest.

Informed consent

Informed consent was obtained from all individuals included in this study.

Ethical approval

Research involving human subjects complied wihtall relevane national regulations, instituional policies and is in accordance with the tenets of the Helsinkin Declaration (as revised in 2013), and has been approved by the authors' Institutional Review Board or equivalent committee (NCT04408170, https://www.condor-platform.org/condor_workstreams/falcon).

Data Availability

The datasets generated during and/or analysed during the current study are available fomr the corresponsind author on reasonable request.

For Review Only

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Jenny Hällqvist[1,2*], Dan Lane[3,4*], Andrew Shapanis[5,6*], Kayleigh Davis[7], Wendy E. Heywood[1], Ivan Doykov[1], Justyna Śpiewak[1], Nana Ghansah[8], Brian Keevil[9], Pankaj Gupta[3,10], Rebekah Jukes-Jones[3,11], Raj Singh[11], Dominic Foley[12], Johannes P.C. Vissers[12], Rebecca Pattison[12], Samantha Ferries[12], Robert Wardle[12], Amy Bartlett[12], Lisa J. Calton[12], Leigh Anderson[13], Morteza Razavi[13], Terry Pearson[13], Matt Pope[13], Richard Yip[13], Leong L. Ng[10,11], Benjamin I. Nicholas[5], Alistair Bailey[5], Dan Noel[6], R. Neil Dalton[14], Simon Heales[8], Christopher Hopley[15], Andrew R. Pitt[16], Perdita Barran[16], Donald J.L. Jones[11] , Kevin Mills[1], Paul Skipp[5,6] and Rachel S. Carling[7,17]

Jenny Hällqvist, Dan Lane and Andrew Shapanis contributed equally to this work.

Operation Moonshot: Rapid translation of a SARS-CoV-2 targeted peptide immunoaffinity liquid chromatography-tandem mass spectrometry test from research into routine clinical use.

Affiliations:

[1]University College London Translational Mass Spectrometry Research Group Unit, London, United Kingdom

[2]UCL Queen Square Institute of Neurology, Queen Square, London, United Kingdom

[3]The Department of Chemical Pathology and Metabolic Diseases, Level 4, Sandringham Building, Leicester Royal Infirmary, Leicester, United Kingdom

[4]Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom

[5]Centre for Proteomic Research, University of Southampton, Southampton, United Kingdom

[6]Biological Sciences, University of Southampton, Southampton, United Kingdom

[7]Biochemical Sciences, Viapath, Guys & St Thomas' NHSFT, London, United Kingdom

[8]Neurometabolic Unit, National Hospital, London, United Kingdom

[9]Department of Biochemistry, Manchester University NHS Trust, Manchester, United Kingdom

[10]Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom

[11]van Geest MS-OMICS facility, Hodgkin Building, University of Leicester, Leicester, United Kingdom

[12]Waters Corporation, Wilmslow, United Kingdom and Milford, MA, USA

[13]SISCAPA Assay Technologies, Inc., Washington DC USA and Victoria BC Canada

[14]WellChild Laboratory, Evelina London Children's Hospital, London, United Kingdom

[15]National Measurement Laboratory, LGC Teddington, United Kingdom

[16]Manchester Institute of Biotechnology, University of Manchester, Manchester, UK

[17]GKT School Medical Education, Kings College London, UK.

*Corresponding Author: Dr Rachel Carling Rachel.carling@kcl.ac.uk, Biochemical Sciences, Viapath, 4th Floor, North Wing, St Thomas' Hospital, Westminster Bridge Rd, London, SE1 7EH, UK. Tel +44 207 188 1283

For Review Only

Abstract:

Objectives: During 2020, the UK's Department of Health and Social Care (DHSC) established the Moonshot programme to fund various diagnostic approaches for the detection of SARS-CoV-2, the pathogen behind the COVID-19 pandemic. Mass spectrometry was one of the technologies proposed to increase testing capacity.

Methods: Moonshot funded a multi-phase development programme, bringing together experts from academia, industry and NHS to develop a state-of-the-art targeted protein assay utilising enrichment and liquid chromatography tandem mass spectrometry (LC-MS/MS) to capture and detect low levels of tryptic peptides derived from SARS-CoV-2 virus. The assay relies on detection of target peptides, ADETQALPQRK (ADE) and AYNVTQAFGR (AYN), derived from the nucleocapsid protein of SARS-CoV-2, measurement of which allowed the specific, sensitive, and robust detection of the virus from nasopharyngeal (NP) swabs. The diagnostic sensitivity and specificity of LC-MS/MS was compared with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) via a prospective study.

Results: Analysis of NP swabs (n=361) with a median RT-qPCR quantification cycle (Cq) of 27 (range 16.7-39.1) demonstrated diagnostic sensitivity of 92.4% (87.4–95.5), specificity of 97.4% (94.0–98.9) and near total concordance with RT-qPCR (Cohen's Kappa 0.90). Excluding Cq > 32 samples, sensitivity was 97.9% (94.1-99.3), specificity 97.4% (94.0-98.9) and Cohen's Kappa 0.95.

Conclusions: This unique collaboration between academia, industry and NHS enabled development, translation, and validation of a SARS-CoV-2 method in NP swabs to be achieved in five months. This pilot provides a model and pipeline for future accelerated development and implementation of LC-MS/MS protein/peptide assays into the routine clinical laboratory.

Keywords: High performance liquid chromatography; laboratory methods & tools; mass spectrometry; proteins.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Coronavirus disease 2019 (COVID-19) is highly prevalent and remains a global issue due to its seasonality and mutability [1]. Measurement of the causal agent (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) is predominantly achieved through measuring viral ribonucleic acid using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) or antigen tests such as lateral flow tests. Due to its widespread use and sensitivity, RT-qPCR is accepted as the gold standard detection method [2]. A variety of other tests have been established that afford applicability to community testing but are less sensitive than RT-qPCR [3] and have variable reliability [4].

The UK Government's Moonshot Programme funded the development of a mass spectrometry (MS) test to detect SARS-CoV-2 in nasopharyngeal (NP) swab samples. Clinical laboratories use mass spectrometry (MS) to measure a range of analytes [5-7] with steroid hormones [8-10], toxicology [11-13] and newborn screening [14-16] being some of the commonest applications. MS can also provide quantitative measurements and although targeted protein analysis is not yet commonplace in clinical laboratories, MS was put forward as a candidate method for detection of COVID-19 [17-18]. The programme was initially set up in three phases:

- P1 - Development of a harmonised LC-MS/MS method for the measurement of SARS-CoV-2 in NP swabs, with multiple research groups employing different approaches to detect the virus. The work of Van Puyvelde et al. [19] was used as a starting point to investigate a range of sample processing, chromatographic options and mass spectrometric end points. Identification of the candidate peptides from the nucleocapsid protein (NCAP), their evaluation in terms of enrichment affinity and LC-MS/MS behaviour, and the subsequent selection of the target peptides has been reported previously [20].
- P2 – Translation of the assay (combined tryptic peptide immunocapture/targeted LC-MS/MS) into NHS laboratories and modification for routine use.
- P3 – Potential upscaling of the assay into hub laboratories for population screening.

This manuscript describes the translation from P1 to P2, and the results obtained after adaption and implementation of the assay in the NHS. In particular, the validation of the method to ISO15189:2012 standards and comparison with RT-qPCR are described.

Materials and methods

Chemicals and reagents

A full list of reagents, standards and internal quality control (IQC) materials are provided (see Supplemental Material, S1).

Study design

For Review Only

https://mc.manuscriptcentral.com/cclm

NP samples were collected with informed consent from patients with symptoms of a coronavirus infection, via the **F**acilitating **A**cce**L**erated **C**linical Validation **O**f **N**ovel Diagnostics of COVID-19 (FALCON) research study (NCT04408170, https://www.condor-platform.org/condor_workstreams/falcon). Samples were collected prospectively between May 2020 and February 2021 from patients recruited in hospital with either query COVID-19 or who have tested positive for COVID-19 and known COVID-19 positive and/or COVID-19 negative community testing. The samples were approved for use by Health Research Authority (HRA) and Health and Care Research Wales (HCRW) and sponsored by Manchester University NHS Foundation Trust (REC: 20/WA/0169). Respiratory samples were collected by swabbing the posterior pharynx and nasal cavity (mid-turbinate) with a flocked NP swab (Miraclean MC-96000). Three separate swabs were collected from each subject. The first two swabs were placed in viral transport medium (VTM) for analysis by RT-qPCR (ThermoFisher TaqPath™ COVID-19 CE-IVD RT-qPCR kit), (ThermoFisher Scientific, Loughborough, UK)). The first swab was analysed at Francis Crick Institute and the second swab was analysed at Lighthouse Laboratory, Milton Keynes. The third swab was collected in ethanol deactivation solution for analysis by MS. The method comparison between LC-MS/MS and RT-qPCR was performed using the swabs analysed by the Francis Crick Institute. Comparison of two independently collected swab samples was performed using the two RT-qPCR assays. Samples were stored at -80°C prior to analysis. The P2 laboratories performed the LC-MS/MS analysis blind.

Sample preparation

Acetone (0.5 mL) was added to a 2 mL 96 deep-well plate and cooled at -20°C for 30 min. Samples and IQC were vortexed (5 sec). Ethanol deactivation solution (500 µL) was removed from each swab collection tube and added to the acetone. The plate was sealed and cooled at -80°C for 10 min, prior to centrifugation (3500 x g, 10 min). The supernatant was discarded and the protein pellet allowed to air dry. *Rapi*Gest™ SF (Waters Corporation, MA, USA), (0.1% in 200 mM ammonium bicarbonate, 200 µL) was added to each well and the plate shaken at room temperature on a thermomixer (1500 g, five min). The swab was transferred from the collection tube into the corresponding well of the plate. The swab handle was removed, and the plate shaken at room temperature on the thermomixer (1500 g, five min). Trypsin solution (3 mg/mL in 10 mM HCl, 20 µL) was added to each well prior to incubation for one hour (37°C, 500 g). The digested solution was removed from the swabs and transferred to a QuanRecovery 700 µL 96 well plate (Waters Corporation). Subsequent sample processing was performed using an Andrew Alliance™ Andrew+™ pipetting robot (Waters Corporation). The automated procedure quenched the tryptic digest by addition of TLCK (0.5 mg/mL in 10 mM HCl, 20 µL) to each well prior to vortex mixing and incubation at room temperature for five min. Stable isotope label (SIL) peptides (20 µL, 0.45 fmol/µL) were added to each well and mixed. SISCAPA beads (10 µL of each monoclonal antibody, ~ 0.01 pmol/mL) were added to each well, with agitation of the beads before addition to the sample after every three wells, and the plate shaken (1700 g) at room temperature for one hour. Wash buffer (0.5 mM CHAPS in PBS, 150 µL) was added to each well and the plate shaken (1700 g) for 30 seconds. Wash buffer was removed from each well and discarded, and the wash step repeated a further two times. Elution buffer (0.5 mM CHAPS, 1% formic acid, 50 µL) was added to each well and the plate was shaken (1500 g) at room temperature for

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

six min. The supernatant was removed from each well and transferred into a QuanRecovery 700 µL 96-well plate. The plate was manually removed from the robot, sealed and placed in the autosampler on a magnetic base to prevent any spurious magnetic particles from being injected into the LC-MS/MS.

LC-MS/MS conditions

Samples (20 µL) were analysed using a Xevo™ TQ-XS MS with electrospray ionisation source coupled to an ACQUITY™ UPLC™ I-Class chromatography system with autosampler (Waters Corporation). Chromatographic separation was achieved on an ACQUITY™ Premier Peptide BEH C18 Column (1.7 µm, 2.1 x 50 mm) with in-line filter (Waters Corporation.). The mobile phase consisted of a water (A) and acetonitrile (B) both containing 0.1% formic acid v/v. Initial conditions were 95% A, changing to 60% A between 0.25 and 2.20 min and then switching to 15% A by 2.30 min and holding for 0.3 min prior to reverting to 95% A by 2.61 min and re-equilibrating for 0.39 min. The flow rate was 0.6 mL/min, the column was held at 40°C and the autosampler at 10°C. The weak needle wash was water containing 0.1% formic acid v/v, the strong needle wash was acetonitrile containing 0.1% formic acid v/v, and the seal wash was water and acetonitrile in the ratio 90:10 v/v. Analysis time was 3.0 min. Mass spectrometer settings were capillary voltage, 0.5 kV, desolvation temperature, 600 °C, desolvation gas flow, 1000 L/hr, and cone gas, 150 L/hr. Cone voltage and collision energy were optimised for each analyte. Data were acquired by Multiple Reaction Monitoring (MRM) in positive-ionisation mode. One quantifier and two qualifier ions were monitored for the target peptides and their respective SILs (see Supplemental Material, Table S1). Dwell times were 17 msec for each transition. Data were processed using MassLynx™ 4.1 and TargetLynx™ software (Waters Corporation). Results were assessed numerically and visually for each peptide. Numerical assessment included review of peak area intensity for each SIL and analyte; concentration; signal:noise ratio; quantifier:qualifier ratio. Visual assessment included review of the individual extracted ion current chromatograms.

For Review Only

Method validation

Acceptable analytical performance was based on the FDA Guidance for Industry Bioanalytical Method Validation criteria [21]. Validation parameters and criterion are described (see Supplemmental Material, S2).

Results

Chromatographic separation of the target peptides, ADE, AYN, and DGI, was achieved, eluting at t_R 0.92, 1.34 and 1.83 min, in total run time of 3.0 min. Replicate injections of extracted samples demonstrated reproducible retention times with %RSDs of ≤1.1. The method showed good selectivity, with no significant interfering peaks detected at the t_R of the analytes/SILs. Typical extracted ion current chromatograms are show in Figure 1A-C.



Figure 1: Extracted ion current chromatograms for the three target peptides A) ADE B) AYN and C) DGI for a SARS-CoV-2 positive sample with a RT-qPCR cycle threshold value of 23.

For Review Only

The calibration curves for AYN and ADE exhibited a linear response over the concentration range 1.8 to 114 amol/µL. For DGI the range was 14.0 to 1136 amol/µL. Correlation coefficients (R^2) of ≥ 0.99 were achieved for all curves apart from one AYN calibration (R^2 = 0.9816).

The method had acceptable sensitivity for both AYN and ADE. The LOD was 0.45 amol/µL (9 amol on-column) for AYN and 3.6 amol/µL (72 amol on-column) for ADE. The LLOQ for both analytes was 3.6 amol/µL. The LOD and LLOQ for DGI were not determined due to significant carry over and this peptide was subsequently excluded from the validation.

Imprecision was satisfactory for both AYN and ADE. The intra-well %RSD was < 5% for both analytes. The intra-batch %RSD for the positive control material was 8.8 and 4.7 for AYN and ADE at concentrations of 14.7 and 8.2 amol/µL, respectively. The inter-batch %RSD for the positive control material was 7.0 and 4.5 for AYN and ADE at concentrations of 14.9 and 8.2 amol/µL respectively. Quantifier to both qualifier ion ratios were reproducible for both peptides with %RSDs of 4.5 and 5.4 for AYN and 2.5 and 3.6 for ADE. Neither AYN nor ADE were detected in the negative control material (25/25).

There was negligible carryover for ADE (peak area of blank was 3% of peak area at LLOQ) whereas some carryover was evident for AYN (peak area of blank was 57% of peak area at LLOQ).

The method demonstrated good selectivity with no interference from Influenza A, B and Rhinovirus (see Supplemental Material, S3 and Figure S3). Background signals were all < 20% of AYN/ADE peak areas at LLOQ and < 5% of the area of the SIL. The mean AYN ion ratio in true positive patient samples was 3.1 (median 2.9, range 1.0-42.2). The mean ADE ion ratio in true positive patient samples was 3.6 (median 3.0, range 0.76–23.7).

Swab extracts remained stable for all analytes when stored at 10 or -80°C for up to 72 hours, with accuracies within ±15% of freshly prepared samples. If necessary, samples can be reconstituted in 0.1% formic acid (20 µL) prior to analysis.

Of the 396 swab samples received, 35 were excluded from the method comparison; 20 due to an inconclusive RT-qPCR result; 11 due to poor sample quality or sampling issues; three due to the absence of a RT-qPCR result; one due to analytical failure. Of the samples in the method comparison, 22% (88/396) were self-collected and 72% (286/396) were collected by a healthcare professional (HCP). Results are summarised in Figure 2A-B and Tables 1 and 2.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



Figure 2: Method comparison of RT-qPCR with LC-MS/MS for A) the AYN peptide and B) the ADE peptide. Results are categorised according to RT-qPCR classification; negative; positive with Ct value > 32; positive with Ct value ≤ 32.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Diagnostic sensitivity and specificity of the peptide immunoaffinity LC-MS/MS method when compared with the ThermoFisher Taqpath RT-qPCR assay.

	All Samples	Samples with Ct ≤ 32	Samples with Ct ≤ 27
Total Samples	361	335	282
False Negative (FN)	13	3	0
False Positive (FP)	5	5	5
True Negative (TN)	185	184	184
True Positive (TP)	158	143	93
Sensitivity (95% CI)	92.4% (87.4 – 95.5)	97.9% (94.1 – 99.3)	100% (95.9 – 100)
Specificity (95% CI)	97.4% (94.0 – 98.9%	97.4% (94.0 – 98.9)	97.4% (96.0 – 100)
Cohen's Kappa	0.8998	0.9515	0.9604
Positive predictive value	96.9%	96.6%	94.9%
Negative predictive value	93.4%	98.4%	100%

Table 2: Breakdown of nasopharyngeal swab results by source of collection.

Source of sample	Total number	False negative	False positive	True positive	True negative	False	Total
RMS2*	88	12 (13.6%)	1 (1.1%)	54 (61.4%)	16 (18.2%)	5 (5.7%)	88
RMS0*	286	12 (4.2%)	4 (1.4%)	98 (34.3%)	157 (54.9%)	15 (5.2%)	286
RMS1*	22	0	0	6 (27.3%)	12 (54.6%)	4 (18.2%)	22
Total no.	396						

RMS0* = Sampling by HCP
RMS1* = Unknown
RMS2* = Self sampling

Cycle-threshold (Cq) values of the n=361 samples in the comparison ranged from 16.7 to 39.1 (median 27). Testing showed near total concordance with the Taqpath RT-qPCR (Cohen's Kappa 0.90) [22]. The LC-MS/MS method had a diagnostic sensitivity of 92.4% (87.4–95.5) and a diagnostic specificity of 97.4% (94.0–98.9). If samples with Cq > 27 were excluded (n=68), the method had a diagnostic sensitivity of 100% (95.9–100) and a diagnostic specificity of 97.4% (96.0-100.0) thus exceeding the target performance criteria set by DHSC and giving Cohen's Kappa = 0.96. As the significance of a positive result with Cq > 32 is generally considered to be unclear when interpreted in isolation, it is pertinent to note that excluding these samples (n=26) gives diagnostic sensitivity of 97.9% (94.1-99.3), specificity of 97.4% (94.0-98.9) and near perfect concordance with RT-qPCR (Cohen's Kappa = 0.95), a performance directly comparable with many commercial RT-qPCR assays.

For the swab samples sequentially collected and analysed by the same RT-qPCR method at two different laboratories, 87.5% of results agreed and 12.5% were discrepant. Of those that were discrepant, 77.8% were void/inconclusive results and 22.2% differed on final classification. Overall, 2.8% (14/502) of samples were classified differently by the

For Review Only

1
2
3 two PCR methods (Table 3). This discrepancy could reasonably be attributed to inconsistency in swabbing efficacy
4
5 and/or analytical performance; these samples had a mean Cq = 33.5 (range 31.0 to 35.8).
6
7 Table 3: Comparison of the Crick Taqpath RT-qPCR assay with the Milton Keynes Taqpath RT-qPCR assay on
8
9 sequentially collected nasopharyngeal swabs. Match based on final classification of Crick & Milton Keynes results.
10

	Crick to Milton Keynes ORF1ab gene comparison	Crick to Milton Keynes N gene comparison	Crick to Milton Keynes S gene comparison	Crick to Milton Keynes MS2 gene comparison
Match*	439	446	106	388
Crick Void, MK positive	1	1	0	57
Crick Void, MK negative	7	6	55	0
Crick Void, MK inconclusive	49	50	2	0
Crick negative, MK positive	6	0	340	0
Crick positive, MK negative	0	0	0	58
FALSE (no MK result)	11	10	10	10
Total	513	513	513	513

*Match based on final classification of Crick & Milton Keynes results for ORF1ab gene

For Review Only

Discussion

This unique collaboration between academia, industry and the NHS resulted in the successful development of a targeted protein assay for the detection of SARS-CoV-2. Furthermore, the test was developed, validated to ISO15189:2012 standard and translated into the NHS within 5 months. This manuscript demonstrates the power of collaboration across this triplex of sectors and highlights the benefits of this approach to clinical diagnostics. Continued communication during the P2 phase was key to success and an invaluable lesson in bridging the gap between research test development and clinical implementation. Currently in the UK there are no defined positions for translational research scientists. This is likely a key factor in why so few biomarkers are successfully translated into clinical use.

Whilst the analytical performance of the AYN and ADE peptides was acceptable, that of DGI was not. It is postulated that this reflects its hydrophobicity (GRAVY score = 0.59) [23] and absorption to surfaces during the analytical process. This highlights the importance of investigating the binding properties and surface reactivity when developing methods and of including multiple target peptides during initial validation [24]. The DGI peptide was subsequently removed from the validated method.

Following translation of the assay into a clinical laboratory, several modifications and refinements were made to facilitate larger scale preparation in a routine environment. The original protocol specified the addition of ethanol storage solution to a 96-well plate prior to precipitation of the protein in ice-cold ethanol. This was a manual process,

prone to error and cross contamination of samples due to the difficulties associated with transferring solvents by pipette. To negate these risks, an acetone precipitation step was evaluated by directly adding the ethanol storage solution to 96-well plates containing pre-cooled acetone (-20°C). The benefit of using acetone as a precipitant was an increase in signal of approximately 20-40%.

Other improvements introduced during the P2 phase included refinement of calibrator concentrations; introduction of matrix matched IQC materials to demonstrate control of the entire analytical process; optimisation of MS conditions to increase sensitivity; automation of the SISCAPA capture using liquid-handling robots; development of a standardised classification algorithm to ensure consistency in interpretation of results. The algorithm is under further development to ensure manual interpretation of the data will not be necessary in future.

Automation of the sample preparation process was essential for such a complex, manual method to be feasible for use in a routine laboratory. With support from industry, the process was automated, reducing batch processing time by two hours and increasing sample throughput by~40%. The validation has also demonstrated the ease with which the SISCAPA workflow could be adapted for future applications.

There are several acknowledged limitations of this study, perhaps the most important being that RT-qPCR and MS methods are not directly comparable. One is direct and measures the amplified signal from viral RNA, the other is in-direct and measures peptides derived from NCAP protein. As RT-qPCR is the accepted gold-standard method of analysis for SARS-CoV-2, it is understandably the point of reference to which novel methods must be compared, however these differences do pose a challenge. RT-qPCR is very sensitive at targeting and detecting one or more gene fragments and can detect non-viable virus thus the prolonged RNA shedding and subsequent positive detection may not correlate to persistence of infectious virus. It is therefore possible that some of the infected people in the validation may have been identified after the infectious period had passed i.e., RT-qPCR testing has poor specificity when used during this phase. Furthermore, RT-qPCR itself is not a perfect test, with drop-out of the S-gene an issue for both Alpha and Omicron variants [25]. Conversely, the methodology of the MS test means that to date, it has proved robust to the presence of emerging COVID-19 variants. The decision to use target peptides derived from the NCAP protein rather than the S-protein reflected the S-proteins proclivity to mutate at a faster rate than NCAP protein and the higher abundance of NCAP protein in the virus compared with S. This has proved advantageous and as new variants appear, the nature of the methodology and the multiplexing capability of MS means that, with minor modifications, the assay can quickly and easily be adapted to include new variants, thus enabling the simultaneous monitoring of multiple variants. To date, the LC-MS/MS assay has proved robust to all but one variant. The B1.617.2 variant, corresponding to D337Y mutation, altered peptide ADE is the only variant in which the mutation affected one of the target peptides. The D377Y mutation altered the target peptide A**D**ETQALPQR to A**Y**ETQALPQR. However, experiments demonstrated that the target peptide was still captured by SISCAPA with high affinity and modification of the MRM, means that the Delta variant could be added to the portfolio of variants detected.

The assay was semi-quantitative, a reflection of the time constraints of the pandemic and the pace at which the method was developed. Inclusion of a normalisation peptide from a protein specific for the NP area would have

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

allowed full quantitation and reflected the efficiency and quality of the sampling process. Subsequent protein analyses of different areas of the mouth, nose and nasopharyngeal area identified a candidate marker, BPI fold-containing family B member 1 (BPIB1) that was highly concentrated in the NP area. Retrospective analysis of the first SISCAPA wash in the validation sample set, demonstrated the potential utility of this protein for normalisation. Three samples classified as false negatives had BPIB1 concentrations <7.5th centile and a further 22 samples classed as either true negative or inconclusive by RT-qPCR also had BPIB1 concentrations <7.5th centile which potentially could have been 'missed' due to poor swabbing. Thus, there would be merit in developing a SISCAPA method against the BPIB1 target peptide, to quality control sample collection and provide a truer reflection of viral load. Although SISCAPA methodology significantly improved the assay, the lead time to create an antibody (~six months) prevented the inclusion of the BPIB1 normalisation step.

Of the samples in the method comparison, 22% (88/396) were self-collected and 72% (286/396) were collected by a healthcare professional (HCP). The percentage of false negatives seen in the self-collected swab group is significantly higher (13.6%) than that seen when sampling is performed by an HCP (4.2%) (Table 2).

It is important to note that the swab used for the MS test was the last of three samples collected from the patient. As swab collection is generally viewed as an unpleasant procedure, it is possible that the efficacy of collection deteriorated, again highlighting the benefit of including a marker of swab integrity in the assay in future.

The design of the FALCON study meant that the validation was performed on separately collected specimens, so in addition to differences in analytical performance, the results of the comparison also reflect any differences in sampling efficacy. To benchmark the likely error rate associated with a method comparison based on separate swab samples, a comparison of the Crick Taqpath RT-qPCR assay with the Milton Keynes Taqpath RT-qPCR assay (n=502) showed a 2.8% error rate, which could reasonably be attributed to inconsistency in sampling efficacy rather than analytical performance (Table 3). The error rate seen when RT-qPCR is compared with RT-qPCR for the measurement of paired, sequentially collected NP swab samples can be used as an estimate of the error rate that sampling efficiency alone could reasonably be expected to contribute to a comparison of MS/MS with RT-qPCR, *i.e.*, over and above the analytical agreement of the two methods. It should also be noted that for five samples, the MS classification was positive and the RT-qPCR negative. This observation could again highlight sampling inconsistencies.

The MS test has comparable performance to other tests used routinely for the detection of COVID-19. It has been demonstrated that 2.8% of results are discordant when a RT-qPCR method is compared with itself and using this as an indicator of the 'allowable' error, a test with a diagnostic sensitivity of 92.4% (87.4–95.5) and 97.4% (94.0–98.9) could be considered to have broadly comparable performance to that reported in the literature for many commercially available RT-qPCR tests.

This study provides an intriguing insight and valuable evidence of the speed with which a complex, multiplexed targeted proteomic assay can be translated into a routine clinical laboratory and validated to ISO15189:2012 standards. In many respects, for those working in the field of MS and clinical diagnostics, the true legacy of the Moonshot project is not the development and validation of the SARS-CoV-2 test itself, it is understanding that a

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

collaborative approach, access to state-of-the-art technology and automation and ring-fenced time for development and translation have been identified as the key components to success.

All Supplemental Tables and Figures are available in the online electronic supplement for this manuscript.

Acknowledgements

This work was funded by the UK Department of Health and Social Care (DHSC) as part of the Moonshot programme. We would also like to thank the Peto Foundation for their kind donations and the NIHR-BRCs at Great Ormond Street Hospital, Leicester, Manchester and Southampton.

Conflict of Interest

LC, DF, TM, JV, RP, AB, SF and RW are employed by Waters Corporation. LA, MR, JP and MP are employed by SISCAPA Assay Technologies. SH and RND were advisors to the DHSC for the duration of this project

None of the other authors declared any potential conflicts of interest.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the post-pandemic period. Science 2020;368:860-8.

2. Holborow A, Asad H, Porter L, Tidswell P, Johnston C, Blyth I, Bone A, et al. The clinical sensitivity of a single SARS-CoV-2 upper respiratory tract RT-PCR test for diagnosing COVID-19 using convalescent antibody as a comparator. Clin Med (Lond) 2020;20:e209-11. doi: 10.7861/clinmed.2020-0555. Epub 2020 Sep 11.

3. Preliminary report from the joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of lateral flow viral antigen detection devices (LFDs) for mass community testing: 2020.

4. Stop-using-innova-medical-group-sars-cov-2-antigen-rapid-qualitative-test-fda-safety-communication, US Food & Drug Administration: Safety Communication 2021.

5. Jannetto PJ, Fitzgerald RL. Effective use of mass spectrometry in the clinical laboratory. Clin Chem 2016;62:92-8.

6. Strathmann FG, Hoofnagle AN. Current and future applications of mass spectrometry to the clinical laboratory. Am J Clin Pathol 2011;136:609-16.

7. Adaway JE, Keevil BG, Owen LJ. Liquid chromatography tandem mass spectrometry in the clinical laboratory. Ann Clin Biochem 2015;52:18-38.

8. Sandhu JK, Auluck J, Ng LL, Jones DJL. Improved analysis of vitamin D metabolites in plasma using liquid chromatography tandem mass spectrometry, and its application to cardiovascular research. Biomed Chromatogr 2014;28:913-917.

9. Keevil B. Steroid mass spectrometry for the diagnosis of PCOS. Med Sci (Basel) 2019;7:78.

10. Keevil BG. LC–MS/MS analysis of steroids in the clinical laboratory. Clin Biochem 2016;49:989-997.

11. Zhang Y, Wei B, Zhu U, Zhang Y, Bluth MH. Liquid chromatography-tandem mass spectrometry: An emerging technology in the toxicology laboratory. Clin Lab Med 2016;36:635-661.

12. Remane D, Wissenbach DK, Peters FT. Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology - an update. Clin Biochem 2016;49:1051-71.

13. Peters FT. Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology. Clin Biochem 2011;44:54-65.

14. Johnson A, Mills K, Clayton P. The use of automated electrospray ionization tandem MS for the diagnosis of inborn errors of metabolism from dried blood spots. Biochem Soc Trans 1196;24:932-8.

15. Carling RS, John C, Goddard P, Griffith C, Cowen S, Hopley C, Moat SJ. Evaluation of a common internal standard material to reduce inter-laboratory variation and ensure the quality, safety and efficacy of expanded newborn screening results when using flow injection analysis tandem mass spectrometry with internal calibration. Int J Neonatal Screen 2020;6:92. doi: 10.3390/ijns6040092.

16. Moat S, George R, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. Int J Neonatal Screen 2020;6:26. 2020 Mar 26 10.3390/ijns6020026

17. Rappold BA. Clinical protein analysis by mass spectrometry: A new higher order. Clin Chem 2021;67:461-462.

18. Marcovina SM, Clouet-Foraison N, Koschinsky ML, Lowenthal MS, Orquillas A, Boffa MB, et al. Development of an LC-MS/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a). Clin Chem 2021;67:490-499.

19. Van Puyvelde B, Van Uytfanghe K, Tytgat O, Van Oudenhove L, Gabriels R, Bouwmeester R, Dalad S, et al. Cov-MS: A community-based template assay for mass spectrometry-based protein detection in SARS-CoV-2 patients. JACS. Au 2021;1:750-765.

20. Hober A, Tran-Minh KH, Foley D, McDonald T, Vissers JP, Pattison R, et al. Rapid and sensitive detection of SARS-CoV-2 infection using quantitative peptide enrichment LC-MS analysis. eLife 2021; 10:e70843. doi: 10.7554/eLife.70843

21. The Food and drug administration agency. Bioanalytical method validation guidance for industry 2018. Available from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry [Accessed 8 Aug 2022]

22. Landis JR, Kock GG. The measurement of observer agreement for categorical data. Biometrics 1977;35:159-74.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157:105-32.

24. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem 2011;414:38-46.

25. Lippi G, Adeli K, Plebani M. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants. Clin Chem Lab Med. 2021 Dec 16. doi: 10.1515/cclm-2021-1287 [Epub ahead of print].

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



For Review Only



For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary material S1

Chemicals and reagents

Synthetic peptides, ADETQALPQRK (ADE), AYNVTQAFGR, (AYN), DGIIWVATEGALN (DGI) and stable isotope labelled (SIL) peptides [U-$^{13}C_6$, $^{15}N_4$-Arg] ADETQALPQRK (ADE), AYNVTQAFGR (AYN) and DGIIWVATEGALN (DGI) were obtained from Cambridge Research biochemicals (Cambridge, UK). High affinity anti-peptide rabbit monoclonal antibodies specific for the three target peptides of SARS-COV-2 nucleoprotein covalently coupled to magnetic beads were purchased from SISCAPA Assay Technologies (Washington DC, USA and Victoria BC, Canada)._Ammonium bicarbonate, N_α-tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK) >99.0% and 3-[(3-cholamidopropyl)dimethylammonio]-1-propansesulfonate hydrate (CHAPS) >98% were purchased from Merck (Dorset, UK). Optima™ LC/MS grade water, acetonitrile and formic acid (99.5%) were from Fisher Chemical, Thermo Fisher Scientific (Loughborough, UK). LC/MS grade HCl (32%) and Rectapur acetone GPR were obtained from VWR International Ltd (Lutterworth, UK). Sequencing grade, bovine pancreatic trypsin (>10,000 units/mg protein) and molecular biology grade phosphate buffered saline, pH 7.4, were sourced from Merck (Dorset, England). RapiGest SF was obtained from Waters (Altrincham, UK). Miraclean MSC-96000 swabs were sourced from Trafalgar Scientific (Leicester, UK). Ethanol storage solution was prepared from ethanol:200 mM ammonium bicarbonate, pH 8 (30:70 v;v). Human Rhinovirus 16-VPO (0.5mg/mL) was obtained from Indoor Biotechnologies (Cardiff, UK). Human Influenza IAV (Hong Kong/45/2019 H3N2) (0.48 mg/mL) and Influenza IVB (Victoria/35/2013 NA) (1.81 mg/mL) were obtained from Native Antigen Company (Oxford, UK). Synthetic saliva and deactivated virus were obtained from LGC (Middlesex, UK).

For Review Only

Standards and Internal Quality Control

Stock standards (100 fmol/µL) of each peptide were prepared by dilution of the individual 10 pmol/µL stocks in 5% acetonitrile, 0.1% formic acid. A mixed working standard solution of AYN and ADE peptides (1 fmol/µL) was prepared in 5% acetonitrile, 0.1% formic acid and used to prepare a set of calibrators at 0, 1.78. 3.55. 7.31 14.2, 28.4, 56.8 and 113.6 amol/µL, respectively. A working standard solution of DGI (1 fmol/µL) was prepared in 5% acetonitrile, 0.1% formic acid and used to prepare a set of calibrators at 0, 17.8. 35.5 73.1 142.0, 284, 568 and 1136 amol/µL respectively.

A mixed standard of the three SIL peptides was prepared by dilution of the individual 10 pmol/µL stocks in 30% acetonitrile, 0.1% formic acid. Working SIL mix (0.2 fmol/µL) was prepared by serial dilution of mixed SIL stock standard in 30% acetonitrile, 0.1% formic acid.

Two levels (negative and positive) of Internal Quality Control (IQC) material were prepared in-house. The negative IQC were replicate NP swabs collected into ethanol storage solution and stored at -80°C prior to analysis. The positive IQC material was a synthetic sample prepared 'on swab' from a solution of synthetic saliva spiked with deactivated virus and stored at -80°C prior to analysis.

Table S1: MRM transitions monitored for each peptide and corresponding stable isotope labelled (SIL) standard.

Peptide	Transition	Collision energy	Quant/Qualifier
SARS_CoV_2_N_AYN y6	563.786 > 679.352	19	Quantifier
SARS_CoV_2_N_AYN y8	563.786 > 892.464	19	Qualifier 1
SARS_CoV_2_N_AYN y5	563.786 > 578.305	19	Qualifier 2
SARS_CoV_2_N_AYN_IS_SIL y6	568.790 > 689.361	19	
SARS_CoV_2_N_AYN_IS_SIL y8	568.790 > 902.472	19	
SARS_CoV_2_N_AYN_IS_SIL y5	568.790 > 588.313	19	
SARS_CoV_2_N_ADE y3	564.786 > 400.230	19	Quantifier
SARS_CoV_2_N_ADE y5	564.786 > 584.351	20	Qualifier 1
SARS_CoV_2_N_ADE y6	564.786 > 712.41	19	Qualifier 2
SARS_CoV_2_N_ADE_IS_SIL y3	569.790 > 410.239	19	
SARS_CoV_2_N_ADE_IS_SIL y5	569.790 > 594.360	20	
SARS_CoV_2_N_ADE_IS_SIL y6	569.790 > 722.418	19	
SARS_CoV_2_N_DGI_y10	842.949 > 1001.526	30	Quantifier
SARS_CoV_2_N_DGI_y11	842.949 > 1100.595	30	Qualifier 1
SARS_CoV_2_N_DGI_y7	562.302 > 700.399	17	Qualifier 2
SARS_CoV_2_N_DGI_IS_SIL y10	846.956 > 1009.540	30	
SARS_CoV_2_N_DGI_IS_SIL y11	846.956 > 1108.649	30	
SARS_CoV_2_N_DGI_IS_SIL y7	564.973 > 708.413	17	

For Review Only

Supplementary material S2.

Method Validation criterion

Synthetic peptide calibration curves, incorporating a zero and seven non-zero calibrators, were obtained by plotting analyte to stable isotope label (SIL) response ratios versus concentration using least squares regression with a weighting of $1/x$. Linearity was confirmed by replicate analysis of the curves in independent run over ten days with an $R^2 > 0.99$ being considered acceptable.

The lower limit of quantification (LLOQ) was defined as the concentration at which the relative standard deviation (RSD) was ≤ 20%, the accuracy was ± 20% of the target value and signal:noise (S:N) > 10. The limit of detection (LOD) was determined by replicate analysis (n=3) of serial dilutions of the lowest calibration standard. The LOD was defined as the concentration at which S:N >10.

Injection reproducibility was determined by replicate analysis of a pooled, extracted patient sample (n=10) with acceptable reproducibility defined as RSD ≤ 5%. Intra-assay imprecision was determined by replicate analysis (n=5) of positive and negative IQC materials in a single analytical run. Inter-assay imprecision was determined by replicate analysis (n=5) of the same materials in five independent runs performed over nine days. The acceptance criterion for the negative control material was 100% correct classification (detected/not detected). The acceptance criterion for the positive control material was an RSD of ≤ 15%.

Carryover was assessed by injection of a solvent blank directly after injection of pooled SARS-CoV-2 positive extracted patient swabs. The peak area of the blank sample was required to be ≤ 20% of the peak area at the LLOQ.

Selectivity was evaluated by analysis of four nucleocapsid (NCAP) protein standard solutions (0, 125, 625 and 1250 amol/µL) spiked with varying concentrations of human Influenza A, B and Rhinovirus (whole virus) (0, 125, 625 and 1250 amol/µL). An acceptable response was defined as <20% of the analyte area at the LLOQ and/or < 5% of the area of the SIL. The reproducibility of ion ratios in true positive patient samples was determined (n=158).

The stability of extracted patient samples was determined by preparing eight patient pools (two SARS-CoV-2 negative, six SARS-CoV-2 positive) and storing at 10°C and -80°C for 24, 48 and 72 hours prior to analysis. In addition, for each storage temperature, one set of pooled samples were simply thawed and analysed and one set of pooled samples was thawed and reconstituted with 0.1 % formic acid (20 µL) prior to analysis. Stability of the analytes in the extracts was confirmed when accuracies were within ±15% of the values from the initial injection.

Method comparison was performed against RT-PCR (Thermofisher TaqPath™ COVID-19 CE-IVD RT-PCR kit, Cat A48067), which is accepted to be the gold standard method of analysis, or at least of detection. Three nasopharyngeal swabs from each subject (n=396) were collected under the umbrella of the FALCON study, the first two swabs were collected into viral transport medium (VTM) and the third swab into ethanol deactivation solution. Diagnostic sensitivity and specificity were used to assess agreement between the methods. The target performance criterion set

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

by the DHSC was > 95% for sensitivity and specificity at RT-qPCR quantification cycle (Cq) < 27. Concordance between the two methods (Cohen's Kappa > 0.8) [1] was a target set by the P2 laboratories.

A comparison of the RT-qPCR (Thermofisher TaqPath™ COVID-19) method performed in two different laboratories was undertaken to benchmark the error rate associated with independently collected samples from the same subject at the same time (n=502).

1. Landis J, Kock G. The measurement of observer agreement for categorical data. Biometrics 1977;35:159-74.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Supplementary material S3.

The method demonstrated good selectivity with no interference from Influenza A, B and Rhinovirus. The selectivity was evaluated by spiking a pool of SARS CoV-2 negative samples with four different levels of nucleocapsid (NCAP) protein (0, 10, 50 and 100 fmol on column), and spiking each NCAP level with four levels of Influenza A, B and Rhinovirus proteins (0, 10, 50 and 100 fmol on column). The NCAP protein peptides AYN and ADE demonstrated a coefficient of variation between 3% and 9%, and between 1% and 13%, respectively.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure S3: Evaluation of the method's selectivity for nucleocapsid (NCAP) protein in samples also containing Influenza A and B, and Rhinovirus. SARS CoV-2 negative samples were spiked with four levels of NCAP (0, 10, 50 and 100 fmol), and each NCAP level was spiked with increasing amounts of Influenza A and B, and Rhinovirus proteins (0, 10, 50 and 100 fmol). No effect on the signal from the NCAP peptides, ADE and AYN, could be detected with increasing amounts of the Influenza and Rhinoviruses.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reviewer: 1

Comments to the Author

The manuscript submitted by Hällqvist et al describes the development and validation of a targeted proteomics assay for the detection of SARS-CoV-2 virus from nasopharyngeal swabs collected from COVID-19 patients. Viral protein-derived peptides were characterized and quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a triple quadrupole platform and stable isotope labelled internal standards. The performance of the assay was evaluated against reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR). Results have been presented showing that three target peptides from SARS-CoV-2 were monitored ADETQALPQRK (ADE), AYNVTQAFGR, (AYN), DGIIWVATEGALN (DGI). The measured concentrations of the two former peptides were reported to have high levels of diagnostic sensitivity and selectivity for SARS-CoV-2 infection when compared to RT-qPCR. This is a very interesting article that highlights the utility of proteomics within the clinic laboratory to investigate a problem of considerable relevance to public health. There are a number of minor points, which the authors should look to address.

We thank the reviewer for their helpful comments which we have addressed as below:

Abstract

It would be useful to outline in the abstract which tryptic peptides were analysed by LC-MS/MS. At present there no indication as to the analytes that were measured. We thank the reviewer for alerting us to this oversight. The methods section of the abstract has been amended to include the target peptides 'ADETQALPQRK (ADE), AYNVTQAFGR, (AYN)'.

Methods - Sample Preparation

Centrifuge speeds should be denoted as 'g' rather than rpm. The term 'rpm' has been replaced with 'g' throughout the manuscript as suggested.

Times are listed as both text and numerals e.g. ten minutes and 10 minutes. The text has been changed to '10' as suggested. Further, minutes has sometimes been abbreviated to min. Be consistent with the format used throughout the manuscript. 'Minutes' has been replaced with 'min' throughout the manuscript as suggested.

Results

Details of how the three target peptides (ADE, AYN and DGI) were identified and/or chosen for inclusion in the assay should be provided. A sentence has been added to the text on p3 and an additional reference provided. It now reads as follows: *Identification of the candidate peptides from the nucleocapsid protein (NCAP), their evaluation in terms of enrichment affinity and LC-MS/MS behaviour, and the subsequent selection of the target peptides has been reported previously [20].*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The units of concentration are sometimes written as 'attomole' or 'amol'. Be consistent with notation. 'Attomol' has been replaced with 'amol' throughout the manuscript as suggested.

Confirm that the multiple reaction monitoring (MRM) transitions shown in Figure 1 correspond to those listed in Table S1. It appears that the MRM transitions for the AYN and ADE peptides may have been transposed. We thank the reviewer for alerting us to this oversight. The title for Figure 1 was incorrect, with (A) being incorrectly identified as AYN not ADE and vice versa. This has now been corrected and figure 1 is now consistent with Table S1.

In Figure 2 the concentration of the AYM peptide is listed on the y-axis of the graph as attomole/μL whereas the concentration of the ADE peptide is listed as attomole/L. Are both sets of units correct? We thank the reviewer for alerting us to this oversight. Both sets of units should be attomole/uL and the axis labels have been amended accordingly in Figure 2 (amol/uL).

For Review Only

Discussion

Could Tables 2 and 3 be moved to the Results section? Tables 2 and 3 have been moved to the results section as suggested.

Reviewer: 2

this is an interesting paper dealing with the development and validation of a targeted proteomics assay for the detection of SARS-CoV-2 virus from nasopharyngeal swabs which deserves a publication after minor revision

Minor criticisms

Units: units concentration should be homogeneously reported in the manuscript The text has been amended to reflect the reviewers suggestion. 'Attomol' have been replaced with 'amol' throughout the manuscript. Likewise, 'minutes' have been replaced with 'min' throughout.

Centrifugation conditions should be reported as "g" and not rpm. The term 'rpm' has been replaced with 'g' throughout the manuscript as suggested.

Tables should be reported in the "Result" section. Tables 2 and 3 have been moved to the results section as suggested.

Discussion: the length should be reduced. The word count has been reduced and is now a total of 3498.